Cargando…

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series

Immune checkpoint inhibitors (ICIs) are being used increasingly in the treatment of several cancers and have been associated with neurological complications including immune checkpoint inhibitor-induced encephalitis (ICI-iE). We present two cases of ICI-iE with the novel agent dostarlimab, which to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marzoughi, Sina, Chen, Tychicus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713022/ https://www.ncbi.nlm.nih.gov/pubmed/34993356 http://dx.doi.org/10.1016/j.ensci.2021.100356

Ejemplares similares

Orbital Apex Syndrome Due to Mucormycosis – Missed on Initial MRI
por: Marzoughi, Sina, et al.
Publicado: (2021)

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin
por: Kim, Ahwon, et al.
Publicado: (2019)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Immune checkpoint inhibitors: friend or foe for osteoporosis
por: Tang, Jun
Publicado: (2023)

Hypothyroidism-induced kidney dysfunction: an under-recognized phenomenon in patients on immune checkpoint inhibitors
por: Tan, Hui Zhuan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
por: Endo, Kei, et al.
Publicado: (2022)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
por: Corrigan, Margaret, et al.
Publicado: (2019)

A Case of Abdominal Pain and Diarrhea Post Immunotherapy: Hypophysitis Associated with Immune Checkpoint Inhibitors
por: Alok, Akankcha, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
por: Hottinger, Andreas F., et al.
Publicado: (2018)

Anti-LGI1 encephalitis following COVID-19 vaccination: a case series
por: Asioli, Gian Maria, et al.
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation
por: He, Zifan, et al.
Publicado: (2020)

Case series: Immune checkpoint inhibitor-induced transverse myelitis
por: Chatterton, Sophie, et al.
Publicado: (2023)

An adult case of metapneumovirus-induced acute encephalitis
por: Mergeay, Matthias, et al.
Publicado: (2019)

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
por: Chen, Yu-Wei, et al.
Publicado: (2021)

Comparing organ‐specific immune‐related adverse events for immune checkpoint inhibitors: A Bayesian network meta‐analysis
por: Li, Meichen, et al.
Publicado: (2021)

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
por: Ogale, S
Publicado: (2018)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
por: Argyriou, Konstantinos, et al.
Publicado: (2022)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life–threatening continuum of neuromuscular and cardiac toxicity
por: Rota, Eugenia, et al.
Publicado: (2018)

Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
por: Wu, Qiuji, et al.
Publicado: (2020)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12fnpm6jglji1t2shctj2o6dkg